Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"KALEO INC","sponsor":"Optinose","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Optinose Announces XHANCE Co-Promotion Agreement with Kal\u00e9o","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved"},{"orgOrder":0,"company":"KALEO INC","sponsor":"pan Canadian Pharmaceutical Alliance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kal\u00e9o and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT\u00ae Auto-Injector","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"KALEO INC","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Enters Into License Agreement with Kal\u00e9o for The Canadian Rights to Allerject\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by KALEO INC

    Menu

    KALEO INC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              KALEO INC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Valeo Pharma Enters Into License Agreement with Kaléo for The Canadian Rights to Allerject®

              Details:

              Under the Agreement, Valeo will be responsible for all commercial and medical activities for ALLERJECT (epinephrine) in Canada for an initial 10 years period.

              Lead Product(s): Epinephrine

              Therapeutic Area: Immunology Product Name: Allerject

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Valeo Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              KALEO INC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kaléo and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT® Auto-Injector

              Details:

              Kaléo has completed negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent regarding ALLERJECT® (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions.

              Lead Product(s): Epinephrine

              Therapeutic Area: Immunology Product Name: Allerject

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: pan Canadian Pharmaceutical Alliance

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              KALEO INC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Optinose Announces XHANCE Co-Promotion Agreement with Kaléo

              Details:

              Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, rapidly increasing promotional reach and frequency.

              Lead Product(s): Fluticasone Propionate

              Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Optinose

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY